|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||1.47 - 1.53|
|52 Week Range||0.71 - 2.76|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||0.32 (34.19%)|
|1y Target Est||N/A|
Invictus Jumps to Top Five in Share Appreciation Among Canada's Leading Cannabis Companies for 2018 Q1
Company Announces Commencement of 40,000 sq. ft. Construction Expansion Project VANCOUVER , March 27, 2018 /PRNewswire/ - INVICTUS MD STRATEGIES CORP. ("Invictus" or the "Company") ...
FRA: 8IS1) is pleased to announce that Acreage Pharms has undergone its physical on site sales license inspection. Health Canada officials are now completing their report. Given Acreage Pharms' strong commitment to closely adhering to regulatory guidelines and requirements, the company remains confident it will pass this important regulatory step and gains its sales license.
FRA: 8IS1) is pleased to announce that today, Gene Simmons, Chief Evangelist Officer for the company and its management team opened the trading day at the TSX Venture Exchange (TSXV). The appearance coincides with the company changing its share ticker from IMH to GENE.
FRA: 8IS1) is pleased to announce that the Company is changing its ticker on the TSX Venture Exchange from IMH to GENE effective on March 20, 2018. "The change in our share ticker to GENE reflects the participation of music legend and media mogul Gene Simmons, who joins Invictus as Chief Evangelist Officer and our enterprise vision of providing multiple genetics/strains to cannabis consumers globally as regulations permit" said Invictus Chairman and CEO Dan Kriznic.
FRA: 8IS1) Acreage Pharms Ltd. ("Acreage Pharms") is pleased to announce that it has received notification from Health Canada (HC) that its sales license inspection has been scheduled for later in March and is anticipated to take up to three days. The Sales License Inspection is the last step prior to the issuance of a Sales License under the Access to Cannabis for Medical Purposes Regulations (the "ACMPR"). "As there are currently only 40 cannabis sales licenses under the ACMPR in Canada, receiving confirmation of our Sales License Inspection from Health Canada is a major milestone for Acreage Pharms.
FRA: 8IS1) Acreage Pharms Ltd. ("Acreage Pharms") is pleased to announce construction of its Phase 2 facility is nearly complete, putting Acreage Pharms on track for 5,000 kg of cannabis production capacity this month. "Facility construction is one of the foundations of our progress at this point, and we are thrilled that our teams of building specialists are completing work on this ambitious schedule on time," said Dan Kriznic, Chairman and CEO of Invictus. Both the Phase 1 and Phase 2 facilities at Acreage Pharms, located in west-central Alberta, have a total of approximately 40,000 square feet with expected 5,000 kg of capacity beginning in February 2018, along with a further planned 80,000 square foot Phase 3 expansion for total combined production capacity of 19,000 kg in 2018.
VANCOUVER , Feb. 5, 2018 /PRNewswire/ - INVICTUS MD STRATEGIES CORP.'s ("Invictus" or the "Company") (TSXV: IMH; OTC: IVITF; FRA: 8IS1) is pleased to announce that it has received an ...
Invictus Receives $16.5 Million from Warrants and Option Exercises Since Dec 22, 2017 and Increases Funded Capacity in 2018 to 27,200 Kg
Invictus MD Jumpstarts Revenue Stream With Sale of First 120 kg of Flower to Canopy Growth Corporation; Signs Definitive Agreement to Increase Ownership of AB Laboratories in Ontario from 33.3% to 50%
FRA: 8IS1) is pleased to announce the sale of its first 120 kg of dried flower from AB Laboratories Inc. (AB Labs), the licensed production facility under the Access to Cannabis for Medical Purposes Regulations ("ACMPR"), near Hamilton to Canopy Growth Corporation (WEED.TO), putting Invictus MD's license holders on track for achieving 26,000 kg run-rate production capacity for 2018 with net capacity of 22,150 kilograms to Invictus MD. Additionally, the Company is pleased to announce that it has signed the definitive agreement to make its further strategic investment in AB Labs, from its current 33.3 percent ownership interest to 50 percent.
Vancouver, British Columbia--(Newsfile Corp. - January 10, 2018) - Trading resumes in: Company: Invictus MD Strategies Corp. TSX-V Symbol: IMH ...
Vancouver, British Columbia--(Newsfile Corp. - January 10, 2018) - The following issues have been halted by IIROC: Company: Invictus MD Strategies Corp. TSX-V Symbol: IMH ...
Invictus MD to Increase Investment in AB Laboratories; AB Laboratories Receives Sales License; AB Laboratories, AB Ventures and Acreage Pharms Target over 26,000 kg Capacity in 2018
VANCOUVER , Jan. 8, 2018 /PRNewswire/ - INVICTUS MD STRATEGIES CORP. ("Invictus MD" or the "Company") (TSXV: IMH; OTC: IVITF; FRA: 8IS1) is pleased to announce that the Company has ...
Vancouver, British Columbia--(Newsfile Corp. - January 5, 2018) - The following issues have been halted by IIROC: Company: Invictus MD Strategies Corp. TSX-V Symbol: IMH ...